60 related articles for article (PubMed ID: 20214038)
1. The combination of selective inhibition of the cannabinoid CB1 receptor and activation of the cannabinoid CB2 receptor yields improved attenuation of motor and autonomic deficits in a mouse model of spinal cord injury.
Heller JE; Baty DE; Zhang M; Li H; Adler M; Ganea D; Gaughan J; Loftus CM; Jallo JI; Tuma RF
Clin Neurosurg; 2009; 56():84-92. PubMed ID: 20214038
[No Abstract] [Full Text] [Related]
2. Cannabinoid CB2 receptor activation attenuates motor and autonomic function deficits in a mouse model of spinal cord injury.
Baty DE; Zhang M; Li H; Erb CJ; Adler MW; Ganea D; Loftus CM; Jallo JI; Tuma RF
Clin Neurosurg; 2008; 55():172-7. PubMed ID: 19248685
[No Abstract] [Full Text] [Related]
3. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation.
Costa B; Giagnoni G; Franke C; Trovato AE; Colleoni M
Br J Pharmacol; 2004 Sep; 143(2):247-50. PubMed ID: 15313881
[TBL] [Abstract][Full Text] [Related]
4. CB1 cannabinoid receptor agonist inhibits matrix metalloproteinase activity in spinal cord injury: A possible mechanism of improved recovery.
Hong J; Nandiwada V; Jones V; Lu M; Warner DS; Mukhopadhyay S; Sheng H
Neurosci Lett; 2015 Jun; 597():19-24. PubMed ID: 25881484
[TBL] [Abstract][Full Text] [Related]
5. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
Sain NM; Liang A; Kane SA; Urban MO
Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975
[TBL] [Abstract][Full Text] [Related]
6. CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice.
Lopez-Rodriguez AB; Siopi E; Finn DP; Marchand-Leroux C; Garcia-Segura LM; Jafarian-Tehrani M; Viveros MP
Cereb Cortex; 2015 Jan; 25(1):35-45. PubMed ID: 23960212
[TBL] [Abstract][Full Text] [Related]
7. Long term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer.
Wright KL; Robertson DA; Moyer MP; Ward SG
Int J Cancer; 2008 Apr; 122(8):1920-1. PubMed ID: 18076045
[No Abstract] [Full Text] [Related]
8. Attenuation of allergic contact dermatitis through the endocannabinoid system.
Karsak M; Gaffal E; Date R; Wang-Eckhardt L; Rehnelt J; Petrosino S; Starowicz K; Steuder R; Schlicker E; Cravatt B; Mechoulam R; Buettner R; Werner S; Di Marzo V; Tüting T; Zimmer A
Science; 2007 Jun; 316(5830):1494-7. PubMed ID: 17556587
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacology of cannabinoid receptors].
Le Fur G; Rinaldi-Carmona M; Barth F; Alexander J
Bull Acad Natl Med; 2007; 191(4-5):933-8; discussion 938-40. PubMed ID: 18225447
[TBL] [Abstract][Full Text] [Related]
10. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.
Teixeira-Clerc F; Julien B; Grenard P; Tran Van Nhieu J; Deveaux V; Li L; Serriere-Lanneau V; Ledent C; Mallat A; Lotersztajn S
Nat Med; 2006 Jun; 12(6):671-6. PubMed ID: 16715087
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoid CB1 receptors are expressed in the mouse urinary bladder and their activation modulates afferent bladder activity.
Walczak JS; Price TJ; Cervero F
Neuroscience; 2009 Mar; 159(3):1154-63. PubMed ID: 19356696
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of selective cannabinoid CB(1) and CB(2) receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis.
Tambaro S; Casu MA; Mastinu A; Lazzari P
Eur J Pharmacol; 2014 Apr; 729():67-74. PubMed ID: 24561047
[TBL] [Abstract][Full Text] [Related]
13. The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat.
Chapman V
Br J Pharmacol; 1999 Aug; 127(8):1765-7. PubMed ID: 10482905
[TBL] [Abstract][Full Text] [Related]
14. CB2 cannabinoid receptors promote mouse neural stem cell proliferation.
Molina-Holgado F; Rubio-Araiz A; García-Ovejero D; Williams RJ; Moore JD; Arévalo-Martín A; Gómez-Torres O; Molina-Holgado E
Eur J Neurosci; 2007 Feb; 25(3):629-34. PubMed ID: 17328768
[TBL] [Abstract][Full Text] [Related]
15. Modulation of inflammatory responses by a cannabinoid-2-selective agonist after spinal cord injury.
Adhikary S; Li H; Heller J; Skarica M; Zhang M; Ganea D; Tuma RF
J Neurotrauma; 2011 Dec; 28(12):2417-27. PubMed ID: 21970496
[TBL] [Abstract][Full Text] [Related]
16. Hypertonic saline as a treatment for acute spinal cord injury: effects on somatic and autonomic outcomes as observed in a mouse model.
Levene HB; Erb CJ; Gaughan JP; Loftus CM; Tuma RF; Jallo JI
Clin Neurosurg; 2007; 54():213-9. PubMed ID: 18504922
[No Abstract] [Full Text] [Related]
17. Involvement of cannabinoid CB1 and CB2 receptor activity in the development of behavioural sensitization to methamphetamine effects in mice.
Landa L; Sulcova A; Slais K
Neuro Endocrinol Lett; 2006; 27(1-2):63-9. PubMed ID: 16648795
[TBL] [Abstract][Full Text] [Related]
18. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
González S; Scorticati C; García-Arencibia M; de Miguel R; Ramos JA; Fernández-Ruiz J
Brain Res; 2006 Feb; 1073-1074():209-19. PubMed ID: 16412990
[TBL] [Abstract][Full Text] [Related]
19. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide.
Murineddu G; Ruiu S; Loriga G; Manca I; Lazzari P; Reali R; Pani L; Toma L; Pinna GA
J Med Chem; 2005 Nov; 48(23):7351-62. PubMed ID: 16279795
[TBL] [Abstract][Full Text] [Related]
20. Mice lacking cannabinoid CB1-, CB2-receptors or both receptors show increased susceptibility to trinitrobenzene sulfonic acid (TNBS)-induced colitis.
Engel MA; Kellermann CA; Burnat G; Hahn EG; Rau T; Konturek PC
J Physiol Pharmacol; 2010 Feb; 61(1):89-97. PubMed ID: 20228420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]